Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 1603-1610

  Houlbrook, S ^a   Harris, A L ^a   Carmichael, J ^b   Stratford, I J ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b General Hospital Nottingham   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Drug resistance; Lung cancer; Topoisomerase II isoforms

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CELL ENZYME; CHLORAMBUCIL; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; MESSENGER RNA; MITOXANTRONE;

ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMSACRINE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE; CHLORAMBUCIL; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; MITOXANTRONE; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0029783626     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA and Struhl K: Current Protocols in Molecular Biology, Wiley Press, USA, 1989.
2. Beck WT, Danks MK, Wolverton JS, Kim R and Chen M: Drug resistance associated with altered DNA topoisomerase II. Advan Enzyme Regul 33: 113-127, 1993.
3. Boege F, Kjeldsen E, Gieseler F, Alsner J and Biersack H: A drug resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and subnuclear distribution. Eur J Biochem 218: 575-584, 1993.
4. Bradley, G Juranka, PF and Ling V: Mechanisms of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
5. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162: 156-159, 1987.
6. Davies SL, Jenkins JR and Hickson ID: Human cells express two differentially spliced forms of topoisomerase II ßmRNA. Nucl Acids Res 21: 3719-3723, 1993.
7. De Isabella P, Capranico G, Binaschi M, Tinelli S and Zunino F: Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. Molecular Pharmacology 37: 11-16, 1989.
8. De Jong S, Koolistra AJ, de Vries EG, Mulder NH and Zijlstra JG: Topoisomerase II as a target of VM-26 and 4'-(acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res 53: 1064-1071, 1993.
9. De Jong S, Zijlstra JG, de Vries EGE and Mulder NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304-309, 1990.
10. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST and Mirabelli CK: Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochem 28: 8154-8160, 1989.
11. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW and Hickson ID: Relationship between Topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592-6595, 1991.
12. Giaccone G, Gazdar AF, Beck H, Zunino F and Capranico G: Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666-1674, 1992.
13. Harker WG, Slade DL, Drake FH and Parr RL: Mitoxantrone resistance in HL-60 leukemia ceils: Reduced nuclear topoisomerase II catalytic activity and drug induced DNA cleavage in association with reduced expression of topoisomerase IIß isoform. Biochem 30: 9953-9961, 1991.
14. Houlbrook S, Addison CM, Davies SL, Carmichael J, Stratford IJ, Harris AL and Hickson ID: Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines, Br J Cancer 72: 1454-1461, 1995.
15. Houlbrook S, Kirk J, Stuart NSA, Stratford IJ, Harris AL, Pettit GR and Carmichael J: Human tumor cell lines: A valuable model for the evaluation of new drugs and for the evaluation of mechanisms underlying cytotoxic drug resistance. Oncol (Life Sci. Adv.) 13: 69-76, 1994.
16. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D and Hickson ID: Isolation of cDNA clones encoding the ß isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucl Acids Res 20: 5587-5592, 1992.
17. Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T and Saijo N: Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84: 113-118. 1992.
18. Kaufmann SH, Karp JE, Jones RJ, Miller CB, Schneider E, Zwelling LA, Cowan K, Wendel K and Burke PJ: Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83: 517-530, 1994.
19. Laemmli UK: Cleavage of structural proteins during the assembly of the head of Bacteriophage T4. Nature (London) 227: 680-685, 1970.
20. Liu LF: DNA topoisomerase Poisons as antitumour druas. Annu Rev Biochem 58: 351-375, 1989.
21. Mayes J, Hinds M, Soares L, Altschuler E, Kim P and Zwelling LA: Further characterisation of an amsacrine-resistant line of HL-60 human leukemia cells and its topoisomerase II. Effects of ATP concentration, anion concentration, and the three-dimensional structure of the DNA target. Biochem Pharmacol 46: 699-707, 1993.
22. Morrow CS and Cowan KH: Multidrug resistance associated with altered topoisomerase II activity - topoisomerase II as targets for rational drug design. J Natl Cancer Inst 82: 638-639, 1990.
23. Peters AC, Smythe AM, Wu L, Monks A, Boyd MR and Shoemaker RH: Levels of messenger-RNA coding for DNA topoisomerase II isoforms do not correlate with in vitro drug sensitivity. Oncol Rep 1: 907-911, 1994.
24. Petrov P, Drake FH, Loranger A, Huang W and Hancock R: Localization of DNA topoisomerase II in Chinese hamster fibroblasts by confocal and electron microscopy. Exp Cell Res 204: 73-81, 1993.
25. Pollack A and Ciancio G: Cell cycle phase-specific analysis of cell viability using Hoechst 3342 and propidium iodide after ethanol preservation. In: Flow Cytometry. (Darzynkiewicz Z and Crissman HA, eds). London Academic Press Inc., 1990, pp 19-24.
26. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM and Wang JC: Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci US 85: 7177-7181, 1988.
27. Wang JC: DNA topoisomerases. Annu Rev Biochem 54: 665-697, 1985.
28. Webb CD, Latham MD, Lock RB and Sullivan DM: Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51. 6543-6549, 1991.
29. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK and Drake FH: Proliferation and cell cycle-dependent differences in expression of the 17G kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth and Differentiation 2: 209-214, 1991.